There are however data supporting a link with adverse outcomes in CCRCC: RAPTOR up-regulation was associated with higher stage and grade, and was a component of an mTOR biomarker panel associated with poor prognosis [68]. The gene discussed is RPTOR; the disease is nonpapillary renal cell carcinoma.